Filtered By:
Drug: Actemra

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 87 results found since Jan 2013.

Tocilizumab for Treating Takayasu's Arteritis and Associated Stroke: A Case Series and Updated Review of the Literature
Takayasu's arteritis (TA) is a rare inflammatory disease that can result in stroke. Treatment of patients with TA requires prolonged use of corticosteroids (CS). We assessed the effectiveness of tocilizumab (TCZ) in inducing disease remission and reducing CS doses in patients with TA.
Source: Journal of Stroke and Cerebrovascular Diseases - April 10, 2015 Category: Neurology Authors: Mohammed Osman, Derek Emery, Elaine Yacyshyn Source Type: research

Giant cell arteritis with vertebral artery involvement —baseline characteristics and follow-up of a monocentric patient cohort
Vertebral artery (VA) involvement in giant cell arteritis (GCA) has rarely been reported. We aimed to evaluate the prevalence, patients’ characteristics, and immunotherapies used in patients with GCA and VA involvement at diagnosis and 1 year follow-up, retrospectively including patients being diagnosed between January 2011 and March 2021 in our department. Clinical features, laboratory data, VA imaging, immunotherapy, and 1 year follow-up data were analyzed. Baseline characteristics were compared to GCA patients without VA involvement. Among all 77 cases with GCA, 29 patients (37.7%) had VA involvement, as diagnosed b...
Source: Frontiers in Neurology - June 26, 2023 Category: Neurology Source Type: research

Godly gift for arthritis pain
Big Pharma is at it again… Creating and selling a drug that causes thousands of heart attacks and strokes each year. In 2015, the FDA asked drug makers to strengthen their warning labels. Since then, most have listed their dangerous side effects on the bottle. But one manufacturer thought they didn’t have to warn people about their dangerous drug. They marketed their product as a “unique” breakthrough. They even published studies promising it was “safe for long-term use.” 1 The drug is a 7-year-old arthritis drug called Actemra. It’s made by the Swiss pharmaceutical company Roche. ...
Source: Al Sears, MD Natural Remedies - October 5, 2017 Category: Complementary Medicine Authors: Al Sears Tags: Anti-Aging Source Type: news

Comparison of the risks of hospitalisation for cardiovascular events in patients with rheumatoid arthritis treated with tocilizumab and etanercept.
CONCLUSIONS: RA patients with TCZ do not have a medium-term excess of CV risk in patients compared with ETN. PMID: 29303702 [PubMed - as supplied by publisher]
Source: Clinical and Experimental Rheumatology - January 6, 2018 Category: Rheumatology Tags: Clin Exp Rheumatol Source Type: research

Literature Commentary
In this issue of Journal of Neuro-Ophthalmology, M. Tariq Bhatti, MD and Mark L. Moster, MD will discuss the following 6 articles: Markus HS, Levi C, King A, Madigan J, Norris J; Cervical Artery Dissection in Stroke Study (CADISS) Investigators. Antiplatelet Therapy vs Anticoagulation Therapy in Cervical Artery Dissection: The Cervical Artery Dissection in Stroke Study (CADISS) Randomized Clinical Trial Final Results. JAMA Neurol. [published ahead of print February 25, 2019] doi: 10.1001/jamaneurol.2019.0072.Cortese I, Muranski P, Enose-Akahata Y, Ha SK, Smith B, Monaco M, Ryschkewitsch C, Major EO, Ohayon J, Schindler MK...
Source: Journal of Neuro-Ophthalmology - August 30, 2019 Category: Opthalmology Tags: Literature Commentary Source Type: research

The use of a Berlin Heart EXCOR LVAD in a child receiving chemotherapy for Castleman's disease
We present the unique case of a pediatric patient who received chemotherapy for a diagnosis of CD, while mechanically supported with a Berlin EXCOR LVAD secondary to restrictive cardiomyopathy. A four‐yr‐old previously healthy male with restrictive cardiomyopathy required MCS after cardiac arrest but was diagnosed with multicentric CD, a non‐malignant lymphoproliferative disorder fueled by excessive IL‐6 production. Treatment with IL‐6 blockade (tocilizumab) every two wk and methylprednisolone had no effect on his lymph nodes or cardiac function while on temporary RotaFlow. A Berlin LVAD was placed for treatment...
Source: Pediatric Transplantation - December 1, 2014 Category: Transplant Surgery Authors: Tamara O. Thomas, Shanmuganathan Chandrakasan, Maureen O'Brien, John L. Jefferies, Thomas D. Ryan, Ivan Wilmot, Michael L. Baker, Peace C. Madueme, David Morales, Angela Lorts Tags: Case Report Source Type: research

Cardiovascular Safety of Tocilizumab versus Tumor Necrosis Factor Inhibitors in Patients with Rheumatoid Arthritis – a Multi‐database Cohort Study
Conclusion: This multi‐database population‐based cohort study found no evidence of an increased CV risk among RA patients who switched from a different biologic drug or tofacitinib to TCZ versus to a TNFi. This article is protected by copyright. All rights reserved.
Source: Arthritis and Rheumatism - February 27, 2017 Category: Rheumatology Authors: Seoyoung C. Kim, Daniel H. Solomon, James R. Rogers, Sara Gale, Micki Klearman, Khaled Sarsour, Sebastian Schneeweiss Tags: Full Length Source Type: research

Adverse Events in Giant Cell Arteritis and Rheumatoid Arthritis Patient Populations: Analyses of Tocilizumab Clinical Trials and Claims Data
ConclusionHigher IRs of AESI were observed in patients with GCA versus those with RA in both TCZ-na ïve and -treated cohorts. Differences in underlying disease, age, and glucocorticoid use may influence AESI incidence, irrespective of intervention.FundingThis study was funded by F. Hoffmann-La Roche Ltd and Genentech, Inc. Article processing charges were funded by F. Hoffmann-La Roche Ltd.Plain Language SummaryPlain language summary is available for this article.
Source: Rheumatology and Therapy - February 1, 2019 Category: Rheumatology Source Type: research

Recurrent Stroke in Giant Cell Arteritis Despite Immunotherapy
Conclusions: This case highlights several important features of strokes in GCA: the predilection for the dural entry point of cerebral blood vessels, the progression of disease despite steroids, and the need to quickly escalate treatment in these cases. As seen in our patient, however, this disease carries high morbidity and mortality and patients often have poor outcomes despite aggressive immunosuppression.
Source: The Neurologist - June 28, 2019 Category: Neurology Tags: Case Report/Case Series Source Type: research

Actemra Rheumatoid Arthritis Drug Tied to Significant Side Effects
Actemra, manufactured by Roche/Genentech, has been associated with heart attack, heart failure, stroke, pancreatitis, lung disease, gastrointestinal perforation, and more
Source: Disabled World - July 24, 2017 Category: Disability Tags: Pharmaceutical Source Type: news

Biological agents reduce cardiovascular events in rheumatoid arthritis non-responsive to tumor necrosis factor-inhibitors – a national cohort study
ConclusionsRA TNFi non-responder patients who received second line tocilizumab or abatacept had more benefit on CV events prevention compared with rituximab.
Source: Canadian Journal of Cardiology - January 16, 2020 Category: Cardiology Source Type: research

European Headache Federation recommendations for neurologists managing giant cell arteritis
ConclusionThe present article will outline recent advances made in the diagnosis and management of GCA.
Source: The Journal of Headache and Pain - March 16, 2020 Category: Neurology Source Type: research

The risk of cardiovascular events associated with disease-modifying antirheumatic drugs in rheumatoid arthritis.
CONCLUSION: Abatacept and TNFi were associated with decreased risk of CVD compared to csDMARDs. Minimizing glucocorticoid use and optimizing MTX dose may improve CV outcomes in patients with RA. PMID: 32801134 [PubMed - as supplied by publisher]
Source: Journal of Rheumatology - August 18, 2020 Category: Rheumatology Tags: J Rheumatol Source Type: research

Neurovascular Causes of Acute Monocular Visual Loss
AbstractPurpose of reviewAcute monocular visual loss may result from a diverse set of neurovascular and systemic disorders and requires urgent evaluation. The goal of this review is to describe the most current understanding of the clinical features, pathophysiology, diagnosis, and treatment of these disorders.Recent findings1. Acute central retinal artery occlusion (CRAO) should be treated as an equivalent to acute ischemic stroke.2. Several recent clinical trials are evaluating the treatment of non-arteritic anterior ischemic optic neuropathy (NAION).3. Tocilizumab is emerging as a first-line steroid-sparing immunomodula...
Source: Current Treatment Options in Cardiovascular Medicine - September 1, 2020 Category: Cardiology Source Type: research

Cardiovascular events and change in cholesterol levels in patients with rheumatoid arthritis treated with tocilizumab: data from the REGATE Registry.
CONCLUSIONS: In current practice, cardiovascular events occurring under TCZ treatment is in the range of what is expected in RA patients despite a global increase in cholesterol levels. PMID: 32896267 [PubMed - as supplied by publisher]
Source: Clinical and Experimental Rheumatology - September 12, 2020 Category: Rheumatology Tags: Clin Exp Rheumatol Source Type: research